RECENT
GENERAL PUBLICATIONS 2001 Tissue engineering. BioCommerce Data’s
Biotechnology Compendium 2001/2, 41-44.
2002 Regenerative Medicine:
Biotechnology’s opportunity to cure heart
disease. BioCommerce Data’s Biotechnology
Compendium 2002/3, 21-35.
Coronary Heart Disease. Biotechnology Investment
Today, 2, 44-50.
Tissue Engineering. Biotechnology Investment
Today, 2, 46.
2003 Tissue engineering. Biotechnology Investment
Today, 2(1), 20-26.
Why all the interest in
tissue-engineered blood vessel. Biotechnology Investment Today, 2(1),
22-23.
How to tissue engineer. Biotechnology Investment
Today, 2( 1), 25.
The future lies in
automation. Biotechnology Investment Today, 2(1),
26-27.
Mason C. (2003).
Automated tissue engineering: A major
paradigm shift in healthcare. Medical Device Technology, 14(1),
16-18.
The age of regenerative
medicine. BioCommerce Data’s Biotechnology
Compendium 2003/4, 1-3.
2004 A
bitter lesson, but tissue engineering learns to refocus on
commercial realities. Clinica World Medical Device &
Diagnostic News 1094, 14.
2005 Mason C. (2005).
Stem cells are big news, but are they big
business? Medical Device Technology, 16(8), 25.
Mason C. (2005).
Regenerative medicine: Revolution in the
making. Medical Device Technology, 16(9), 22.
Mason C. (2005).
Tissue Engineering: A paradigm shift in
wound care. Medical Device Technology. 16(10),
32-33.
2006 Mason C. (2006).
Other approaches to fighting
cardiovascular disease: Stem cells and engineered
tissue. Medical Device Technology. 17(1),
26-27.
Mason C. (2006).
The Korean stem cell fiasco: Shifting the
focus. Medical Device Technology. 17(2),
24-26.
Mason C. (2006).
Stem Cells: The blue print for the
future. Medical Device Technology. 17(3),
32-33.
Mason C. (2006).
The time has come to engineer tissues and
not just tissue engineer. Regenerative Medicine. 1(3), 303-306.
Mason C. and Hoare M.
(2006). Regenerative Medicine Bioprocessing: The
need to learn from the experience of other
fields. Regenerative Medicine. 1(5),
615–623.
Mason C. (2006).
A blueprint for the future. Innovation UK. 50-51.
Stephenson E.L., Braude
P.B. and Mason C. (2006) Proposal for a universal minimum information
convention for the reporting on the derivation of human
embryonic stem cell lines. Regenerative Medicine. 1(6), 739-750.
DTI Global Watch
Mission Report - "Advanced cell & tissue therapies - A
mission to the US" September 2006.
2007 Mason C. (2007).
Regenerative Medicine 2.0 (RegenMed 2.0) Regenerative Medicine.
2(1), 11-18.
Mason C. and Hoare M.
(2007). Regenerative Medicine Bioprocessing:
Building a Conceptual Framework Based on Early
Studies. Tissue
Engineering 13(2), 301-311.
Mason C. (2007).
Regenerative Medicine - The Industry
Comes of Age. Medical Device Technology. March/April
2007, 25-28.
Mason C. and Dunnill P.
(2007). Translational Regenerative Medicine
Research: Essential to Discovery and
Outcome. Regenerative Medicine 2(3), 227-229.
West M.D. and Mason C.
(2007). Mapping the human embryome: 1 to 10e13
and all the cells in between. Regenerative Medicine 2(4), 329-333.
Stephenson E.L., Braude
P.B. and Mason C. (2007). International community consensus
standard for reporting derivation of human embryonic
stem cell lines. Regenerative Medicine. 2(4), 349-362.
Mason C. and Dunnill P.
(2007). Good for UK health and
wealth. Innovation UK, 28-31.
Mason C. and Dunnill P.
(2007). Lessons for the nascent regenerative
medicine industry from the biotech
sector. Regenerative Medicine. 2(5), 753-756.
(Includes the definition of the term, "regen" )
2008 Mason C. and Dunnill P.
(2008). A brief definition of regenerative
medicine Regenerative Medicine. 3(1) 1–5.
